The results of our study suggest that the PDK-1 signaling pathway might be a promising therapeutic target for the treatment of breast cancer and that PDK1 expression should be tested in addition to PIK3CA status in patients with breast cancer prior to beginning therapy. This evidence concerns the gene PIK3CA and breast cancer.